25 XP   0   0   10

Vertex Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Vertex Pharmaceuticals Inc together

PenkeI guess you are interested in Vertex Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Vertex Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Vertex Pharmaceuticals Inc

I send you an email if I find something interesting about Vertex Pharmaceuticals Inc.

Quick analysis of Vertex Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Vertex Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
40.0%

What is your share worth?

Current worth
$67.49
Expected worth in 1 year
$122.65
How sure are you?
80.0%

+ What do you gain per year?

Total Gains per Share
$55.16
Return On Investment
13.8%

For what price can you sell your share?

Current Price per Share
$401.08
Expected price per share
$356.71 - $421.45
How sure are you?
50%

1. Valuation of Vertex Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$401.08

Intrinsic Value Per Share

$57.89 - $177.45

Total Value Per Share

$125.37 - $244.93

2. Growth of Vertex Pharmaceuticals Inc (5 min.)




Is Vertex Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$17.5b$13.9b$3.6b20.9%

How much money is Vertex Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money$3.6b$3.3b$297.6m8.2%
Net Profit Margin36.8%37.2%--

How much money comes from the company's main activities?

3. Financial Health of Vertex Pharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#4 / 1007

Most Revenue
#9 / 1007

Most Profit
#6 / 1007

Most Efficient
#40 / 1007

What can you expect buying and holding a share of Vertex Pharmaceuticals Inc? (5 min.)

Welcome investor! Vertex Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Vertex Pharmaceuticals Inc.

What can you expect buying and holding a share of Vertex Pharmaceuticals Inc?

First you should know what it really means to hold a share of Vertex Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Vertex Pharmaceuticals Inc is $401.08. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Vertex Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Vertex Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $67.49. Based on the TTM, the Book Value Change Per Share is $13.79 per quarter. Based on the YOY, the Book Value Change Per Share is $14.84 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Vertex Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps13.893.5%13.893.5%12.823.2%10.112.5%5.421.4%
Usd Book Value Change Per Share13.793.4%13.793.4%14.843.7%10.082.5%6.221.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.290.1%0.150.0%
Usd Total Gains Per Share13.793.4%13.793.4%14.843.7%10.362.6%6.381.6%
Usd Price Per Share406.89-406.89-288.78-274.11-200.44-
Price to Earnings Ratio29.28-29.28-22.52-29.53-4.52-
Price-to-Total Gains Ratio29.50-29.50-19.47-28.22--911.05-
Price to Book Ratio6.03-6.03-5.38-6.72-13.43-
Price-to-Total Gains Ratio29.50-29.50-19.47-28.22--911.05-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share401.08
Number of shares2
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.29
Usd Book Value Change Per Share13.7910.08
Usd Total Gains Per Share13.7910.36
Gains per Quarter (2 shares)27.5820.72
Gains per Year (2 shares)110.3382.90
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1011010028173
202212105161156
303313207242239
404414309322322
5055254011403405
6066265014484488
7077276016564571
8088387018645654
9099398021725737
1001103109023806820

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%7.03.00.070.0%9.024.00.027.3%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%8.02.00.080.0%21.012.00.063.6%
Dividend per Share0.00.01.00.0%1.00.02.033.3%3.00.02.060.0%4.00.06.040.0%5.00.028.015.2%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%8.02.00.080.0%21.012.00.063.6%

Fundamentals of Vertex Pharmaceuticals Inc

About Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Fundamental data was last updated by Penke on 2024-05-04 07:29:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is fair priced.

1.1. Profitability of Vertex Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Vertex Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Vertex Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 36.8% means that $0.37 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Vertex Pharmaceuticals Inc:

  • The MRQ is 36.8%. The company is making a huge profit. +2
  • The TTM is 36.8%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ36.8%TTM36.8%0.0%
TTM36.8%YOY37.2%-0.4%
TTM36.8%5Y35.4%+1.4%
5Y35.4%10Y6.8%+28.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ36.8%-207.2%+244.0%
TTM36.8%-214.6%+251.4%
YOY37.2%-281.4%+318.6%
5Y35.4%-428.1%+463.5%
10Y6.8%-595.4%+602.2%
1.1.2. Return on Assets

Shows how efficient Vertex Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Vertex Pharmaceuticals Inc to the Biotechnology industry mean.
  • 15.9% Return on Assets means that Vertex Pharmaceuticals Inc generated $0.16 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Vertex Pharmaceuticals Inc:

  • The MRQ is 15.9%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 15.9%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ15.9%TTM15.9%0.0%
TTM15.9%YOY18.3%-2.4%
TTM15.9%5Y17.8%-1.9%
5Y17.8%10Y7.2%+10.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.9%-12.9%+28.8%
TTM15.9%-12.3%+28.2%
YOY18.3%-11.2%+29.5%
5Y17.8%-13.5%+31.3%
10Y7.2%-15.1%+22.3%
1.1.3. Return on Equity

Shows how efficient Vertex Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Vertex Pharmaceuticals Inc to the Biotechnology industry mean.
  • 20.6% Return on Equity means Vertex Pharmaceuticals Inc generated $0.21 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Vertex Pharmaceuticals Inc:

  • The MRQ is 20.6%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 20.6%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ20.6%TTM20.6%0.0%
TTM20.6%YOY23.9%-3.3%
TTM20.6%5Y23.6%-3.1%
5Y23.6%10Y5.2%+18.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ20.6%-16.5%+37.1%
TTM20.6%-15.7%+36.3%
YOY23.9%-14.1%+38.0%
5Y23.6%-18.8%+42.4%
10Y5.2%-19.7%+24.9%

1.2. Operating Efficiency of Vertex Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Vertex Pharmaceuticals Inc is operating .

  • Measures how much profit Vertex Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Vertex Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 38.1% means the company generated $0.38  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Vertex Pharmaceuticals Inc:

  • The MRQ is 38.1%. The company is operating very efficient. +2
  • The TTM is 38.1%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ38.1%TTM38.1%0.0%
TTM38.1%YOY48.2%-10.1%
TTM38.1%5Y39.6%-1.5%
5Y39.6%10Y5.7%+33.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ38.1%-287.3%+325.4%
TTM38.1%-226.2%+264.3%
YOY48.2%-287.8%+336.0%
5Y39.6%-459.1%+498.7%
10Y5.7%-598.1%+603.8%
1.2.2. Operating Ratio

Measures how efficient Vertex Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.62 means that the operating costs are $0.62 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Vertex Pharmaceuticals Inc:

  • The MRQ is 0.619. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.619. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.619TTM0.6190.000
TTM0.619YOY0.511+0.108
TTM0.6195Y0.602+0.016
5Y0.60210Y0.919-0.316
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6193.246-2.627
TTM0.6193.303-2.684
YOY0.5113.753-3.242
5Y0.6025.557-4.955
10Y0.9197.396-6.477

1.3. Liquidity of Vertex Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Vertex Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.99 means the company has $3.99 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Vertex Pharmaceuticals Inc:

  • The MRQ is 3.987. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.987. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.987TTM3.9870.000
TTM3.987YOY5.217-1.230
TTM3.9875Y4.572-0.584
5Y4.57210Y25.939-21.367
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.9873.821+0.166
TTM3.9874.161-0.174
YOY5.2175.313-0.096
5Y4.5726.113-1.541
10Y25.9396.474+19.465
1.3.2. Quick Ratio

Measures if Vertex Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Vertex Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 3.84 means the company can pay off $3.84 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Vertex Pharmaceuticals Inc:

  • The MRQ is 3.843. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.843. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.843TTM3.8430.000
TTM3.843YOY5.141-1.297
TTM3.8435Y4.706-0.863
5Y4.70610Y27.895-23.189
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.8433.474+0.369
TTM3.8433.993-0.150
YOY5.1415.388-0.247
5Y4.7066.105-1.399
10Y27.8956.442+21.453

1.4. Solvency of Vertex Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Vertex Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Vertex Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.23 means that Vertex Pharmaceuticals Inc assets are financed with 22.7% credit (debt) and the remaining percentage (100% - 22.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Vertex Pharmaceuticals Inc:

  • The MRQ is 0.227. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.227. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.227TTM0.2270.000
TTM0.227YOY0.233-0.007
TTM0.2275Y0.247-0.021
5Y0.24710Y0.358-0.111
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2270.347-0.120
TTM0.2270.340-0.113
YOY0.2330.272-0.039
5Y0.2470.368-0.121
10Y0.3580.388-0.030
1.4.2. Debt to Equity Ratio

Measures if Vertex Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Vertex Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 29.3% means that company has $0.29 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Vertex Pharmaceuticals Inc:

  • The MRQ is 0.293. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.293. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.293TTM0.2930.000
TTM0.293YOY0.305-0.012
TTM0.2935Y0.329-0.037
5Y0.32910Y0.637-0.308
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2930.395-0.102
TTM0.2930.411-0.118
YOY0.3050.339-0.034
5Y0.3290.438-0.109
10Y0.6370.469+0.168

2. Market Valuation of Vertex Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Vertex Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Vertex Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of 29.28 means the investor is paying $29.28 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Vertex Pharmaceuticals Inc:

  • The EOD is 28.865. Based on the earnings, the company is overpriced. -1
  • The MRQ is 29.284. Based on the earnings, the company is overpriced. -1
  • The TTM is 29.284. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD28.865MRQ29.284-0.418
MRQ29.284TTM29.2840.000
TTM29.284YOY22.523+6.760
TTM29.2845Y29.526-0.243
5Y29.52610Y4.516+25.011
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD28.865-2.437+31.302
MRQ29.284-2.599+31.883
TTM29.284-2.764+32.048
YOY22.523-4.018+26.541
5Y29.526-6.401+35.927
10Y4.516-6.590+11.106
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Vertex Pharmaceuticals Inc:

  • The EOD is 31.865. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 32.326. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 32.326. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD31.865MRQ32.326-0.462
MRQ32.326TTM32.3260.000
TTM32.326YOY19.062+13.264
TTM32.3265Y26.817+5.509
5Y26.81710Y20.029+6.788
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD31.865-3.111+34.976
MRQ32.326-3.321+35.647
TTM32.326-3.598+35.924
YOY19.062-5.480+24.542
5Y26.817-8.353+35.170
10Y20.029-8.955+28.984
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Vertex Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 6.03 means the investor is paying $6.03 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Vertex Pharmaceuticals Inc:

  • The EOD is 5.943. Based on the equity, the company is overpriced. -1
  • The MRQ is 6.029. Based on the equity, the company is overpriced. -1
  • The TTM is 6.029. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD5.943MRQ6.029-0.086
MRQ6.029TTM6.0290.000
TTM6.029YOY5.378+0.651
TTM6.0295Y6.721-0.692
5Y6.72110Y13.426-6.705
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.9432.051+3.892
MRQ6.0292.143+3.886
TTM6.0292.120+3.909
YOY5.3782.878+2.500
5Y6.7213.601+3.120
10Y13.4263.972+9.454
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Vertex Pharmaceuticals Inc.

3.1. Institutions holding Vertex Pharmaceuticals Inc

Institutions are holding 97.111% of the shares of Vertex Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Vanguard Group Inc8.62120.1981222821802988241.3593
2023-12-31BlackRock Inc8.4660.22721881203-704023-3.1172
2023-12-31Capital World Investors8.43681.57821805770382410321.2667
2023-12-31FMR Inc5.02190.405712979511-1380926-9.6162
2023-12-31State Street Corporation4.67530.239212083818442720.3677
2023-12-31AllianceBernstein L.P.2.72371.10227039738-486718-6.4668
2023-12-31T. Rowe Price Associates, Inc.2.27790.32195887412-962654-14.0532
2023-12-31Geode Capital Management, LLC2.19510.24095673419774451.3839
2023-12-31JPMorgan Chase & Co2.17610.21995624265-481587-7.8873
2023-12-31Wellington Management Company LLP2.0230.39665228538-1297313-19.8796
2023-12-31Jennison Associates LLC1.52631.196239449131472483.8773
2023-12-31Massachusetts Financial Services Company1.40290.47653625802-265992-6.8347
2023-12-31Capital Research Global Investors1.38040.357135676641950805.7843
2023-12-31Loomis, Sayles & Company LP1.21291.95333134852-28616-0.9046
2023-12-31NORGES BANK1.17710.2163304228859076724.098
2023-12-31Morgan Stanley - Brokerage Accounts1.15320.106929804551103543.845
2023-12-31Goldman Sachs Group Inc1.14910.10852969868127454375.1799
2023-12-31Amundi1.05170.5148271811777469639.8625
2023-12-31Northern Trust Corp1.03710.19742680597-132966-4.7259
2023-12-31UBS Asset Mgmt Americas Inc1.00590.41622599904-173895-6.2692
Total 58.713610.4727151750314+1422642+0.9%

3.2. Funds holding Vertex Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-31American Funds Growth Fund of Amer A3.15021.241981420867206129.7098
2024-03-31Vanguard Total Stock Mkt Idx Inv3.14370.2128125184401310.4964
2023-12-31Capital Group Growth Fnd of Amer Comp2.87141.21277421474135321122.2998
2024-03-31Vanguard Institutional 500 Index Trust2.5130.24426495055612710.9523
2024-03-31Invesco QQQ Trust1.87340.7809484188000
2024-03-31American Funds American Balanced A1.61650.7879417809068922819.7551
2024-03-31American Funds New Perspective A1.45331.1616375621454720317.0521
2024-02-29Fidelity Contrafund1.341.1013463227-84900-2.3928
2023-12-31Capital Group New Perspective Comp1.24161.030632090111604665.2637
2024-03-31SPDR® S&P 500 ETF Trust1.20230.24363107564-24174-0.7719
2024-02-29Fidelity 500 Index1.19570.25243090507310981.0165
2024-03-31American Funds Capital World Gr&Inc A1.09130.9495282043926362510.3107
2024-03-28iShares Core S&P 500 ETF1.03350.24382671115195840.7386
2023-12-31Capital Group World Growth & Inc Cmp0.98930.885255681444511921.0788
2024-03-31Vanguard Growth Index Investor0.94580.45112444526493072.0586
2024-03-31American Funds Washington Mutual A0.92440.5541238920947916625.0867
2024-03-31Health Care Select Sector SPDR® ETF0.74811.96711933440-9744-0.5014
2023-12-31Capital Group Wash Mutual Invtrs Comp0.7390.462119100431200006.7037
2023-12-31Vanguard Health Care Inv0.71911.62921858518-840441-31.1395
2024-02-29AllianceBernstein US L/C Growth Eqty MF0.70192.87681814140427912.4157
Total 29.493518.287576228536+4063553+5.3%

3.3. Insider Transactions

Insiders are holding 0.112% of the shares of Vertex Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-26Ourania TatsisSELL354425.7
2024-02-20Ourania TatsisSELL480420.79
2024-02-12Amit SachdevSELL3222420.24
2024-02-12Jeffrey M LeidenSELL2656419.51
2024-02-12Kristen AmbroseSELL1374420.24
2024-02-12Stuart A ArbuckleSELL4295420.24
2024-01-08Jeffrey M LeidenSELL6648419.07
2023-11-06Bruce I SachsSELL11250385
2023-10-31Carmen BozicSELL5651355.92
2023-10-17Carmen BozicSELL5651373.25
2023-10-17Sangeeta N BhatiaSELL243375
2023-10-16Jeffrey M LeidenSELL12962374
2023-10-06Sangeeta N BhatiaSELL242360
2023-10-03Carmen BozicSELL5651345.28
2023-10-02Jonathan BillerSELL610346.76
2023-09-19Carmen BozicSELL5651351
2023-08-23Ourania TatsisSELL2500355
2023-08-09David AltshulerSELL63345.51
2023-08-09Sangeeta N BhatiaSELL242345.51

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Vertex Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--13.79113.7910%14.835-7%10.075+37%6.224+122%
Book Value Per Share--67.48767.4870%53.696+26%43.274+56%25.503+165%
Current Ratio--3.9873.9870%5.217-24%4.572-13%25.939-85%
Debt To Asset Ratio--0.2270.2270%0.233-3%0.247-8%0.358-37%
Debt To Equity Ratio--0.2930.2930%0.305-4%0.329-11%0.637-54%
Dividend Per Share----0%-0%0.287-100%0.152-100%
Eps--13.89513.8950%12.821+8%10.107+37%5.420+156%
Free Cash Flow Per Share--12.58712.5870%15.149-17%10.820+16%5.821+116%
Free Cash Flow To Equity Per Share--10.42910.4290%14.888-30%8.912+17%5.183+101%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--177.446--------
Intrinsic Value_10Y_min--57.886--------
Intrinsic Value_1Y_max--13.539--------
Intrinsic Value_1Y_min--5.875--------
Intrinsic Value_3Y_max--43.913--------
Intrinsic Value_3Y_min--17.693--------
Intrinsic Value_5Y_max--78.184--------
Intrinsic Value_5Y_min--29.463--------
Market Cap103662738928.640-2%105994845000.000105994845000.0000%74822898000.000+42%71443429354.080+48%52116686230.568+103%
Net Profit Margin--0.3680.3680%0.372-1%0.354+4%0.068+438%
Operating Margin--0.3810.3810%0.482-21%0.396-4%0.057+574%
Operating Ratio--0.6190.6190%0.511+21%0.602+3%0.919-33%
Pb Ratio5.943-1%6.0296.0290%5.378+12%6.721-10%13.426-55%
Pe Ratio28.865-1%29.28429.2840%22.523+30%29.526-1%4.516+548%
Price Per Share401.080-1%406.890406.8900%288.780+41%274.112+48%200.443+103%
Price To Free Cash Flow Ratio31.865-1%32.32632.3260%19.062+70%26.817+21%20.029+61%
Price To Total Gains Ratio29.083-1%29.50429.5040%19.466+52%28.220+5%-911.051+3188%
Quick Ratio--3.8433.8430%5.141-25%4.706-18%27.895-86%
Return On Assets--0.1590.1590%0.183-13%0.178-10%0.072+121%
Return On Equity--0.2060.2060%0.239-14%0.236-13%0.052+299%
Total Gains Per Share--13.79113.7910%14.835-7%10.362+33%6.376+116%
Usd Book Value--17580400000.00017580400000.0000%13912700000.000+26%11273031800.000+56%6636972200.000+165%
Usd Book Value Change Per Share--13.79113.7910%14.835-7%10.075+37%6.224+122%
Usd Book Value Per Share--67.48767.4870%53.696+26%43.274+56%25.503+165%
Usd Dividend Per Share----0%-0%0.287-100%0.152-100%
Usd Eps--13.89513.8950%12.821+8%10.107+37%5.420+156%
Usd Free Cash Flow--3278900001.0003278900001.0000%3925200000.000-16%2820036800.200+16%1516496000.100+116%
Usd Free Cash Flow Per Share--12.58712.5870%15.149-17%10.820+16%5.821+116%
Usd Free Cash Flow To Equity Per Share--10.42910.4290%14.888-30%8.912+17%5.183+101%
Usd Market Cap103662738928.640-2%105994845000.000105994845000.0000%74822898000.000+42%71443429354.080+48%52116686230.568+103%
Usd Price Per Share401.080-1%406.890406.8900%288.780+41%274.112+48%200.443+103%
Usd Profit--3619600000.0003619600000.0000%3322000000.000+9%2634442000.000+37%1412386800.000+156%
Usd Revenue--9839000000.0009839000000.0000%8930700000.000+10%7342520800.000+34%4556378100.000+116%
Usd Total Gains Per Share--13.79113.7910%14.835-7%10.362+33%6.376+116%
 EOD+4 -4MRQTTM+0 -0YOY+13 -205Y+25 -1010Y+28 -7

4.2. Fundamental Score

Let's check the fundamental score of Vertex Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1528.865
Price to Book Ratio (EOD)Between0-15.943
Net Profit Margin (MRQ)Greater than00.368
Operating Margin (MRQ)Greater than00.381
Quick Ratio (MRQ)Greater than13.843
Current Ratio (MRQ)Greater than13.987
Debt to Asset Ratio (MRQ)Less than10.227
Debt to Equity Ratio (MRQ)Less than10.293
Return on Equity (MRQ)Greater than0.150.206
Return on Assets (MRQ)Greater than0.050.159
Total8/10 (80.0%)

4.3. Technical Score

Let's check the technical score of Vertex Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.640
Ma 20Greater thanMa 50398.431
Ma 50Greater thanMa 100409.298
Ma 100Greater thanMa 200413.873
OpenGreater thanClose401.500
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets22,730,200
Total Liabilities5,149,800
Total Stockholder Equity17,580,400
 As reported
Total Liabilities 5,149,800
Total Stockholder Equity+ 17,580,400
Total Assets = 22,730,200

Assets

Total Assets22,730,200
Total Current Assets14,144,200
Long-term Assets8,586,000
Total Current Assets
Cash And Cash Equivalents 10,372,300
Short-term Investments 849,200
Net Receivables 1,563,400
Inventory 738,800
Other Current Assets 620,500
Total Current Assets  (as reported)14,144,200
Total Current Assets  (calculated)14,144,200
+/-0
Long-term Assets
Property Plant Equipment 1,452,900
Goodwill 1,088,000
Long Term Investments 2,497,800
Intangible Assets 839,900
Long-term Assets Other 796,700
Long-term Assets  (as reported)8,586,000
Long-term Assets  (calculated)6,675,300
+/- 1,910,700

Liabilities & Shareholders' Equity

Total Current Liabilities3,547,400
Long-term Liabilities1,602,400
Total Stockholder Equity17,580,400
Total Current Liabilities
Short-term Debt 83,700
Accounts payable 364,900
Other Current Liabilities 2,928,500
Total Current Liabilities  (as reported)3,547,400
Total Current Liabilities  (calculated)3,377,100
+/- 170,300
Long-term Liabilities
Capital Lease Obligations 808,400
Long-term Liabilities Other 196,300
Long-term Liabilities  (as reported)1,602,400
Long-term Liabilities  (calculated)1,004,700
+/- 597,700
Total Stockholder Equity
Common Stock2,600
Retained Earnings 10,142,400
Accumulated Other Comprehensive Income -14,300
Other Stockholders Equity 7,449,700
Total Stockholder Equity (as reported)17,580,400
Total Stockholder Equity (calculated)17,580,400
+/-0
Other
Capital Stock2,600
Cash and Short Term Investments 11,221,500
Common Stock Shares Outstanding 260,500
Current Deferred Revenue170,300
Liabilities and Stockholders Equity 22,730,200
Net Debt -9,563,900
Net Invested Capital 17,580,400
Net Working Capital 10,596,800
Property Plant and Equipment Gross 2,641,800
Short Long Term Debt Total 808,400



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-311999-12-311998-12-311997-12-311996-12-311995-12-311994-12-311993-12-311992-12-311991-12-311990-12-31
> Total Assets 
9,200
57,100
51,000
61,000
116,200
99,000
143,500
295,600
266,300
232,400
772,881
925,131
815,720
724,411
545,453
548,998
921,579
601,477
980,479
1,955,496
1,725,446
2,204,280
2,759,288
2,319,041
2,336,309
2,497,045
2,893,785
3,546,014
6,245,898
8,318,465
11,751,808
13,432,500
18,150,900
22,730,200
22,730,20018,150,90013,432,50011,751,8088,318,4656,245,8983,546,0142,893,7852,497,0452,336,3092,319,0412,759,2882,204,2801,725,4461,955,496980,479601,477921,579548,998545,453724,411815,720925,131772,881232,400266,300295,600143,50099,000116,20061,00051,00057,1009,200
   > Total Current Assets 
4,600
51,700
44,000
53,100
106,900
87,900
132,200
281,600
248,700
195,200
403,186
776,092
656,572
593,806
406,712
385,055
771,406
496,851
867,581
1,307,034
1,057,039
1,331,254
1,589,585
1,588,576
1,548,141
1,355,094
1,761,006
2,483,328
3,702,290
4,609,314
7,825,026
9,014,800
12,681,300
14,144,200
14,144,20012,681,3009,014,8007,825,0264,609,3143,702,2902,483,3281,761,0061,355,0941,548,1411,588,5761,589,5851,331,2541,057,0391,307,034867,581496,851771,406385,055406,712593,806656,572776,092403,186195,200248,700281,600132,20087,900106,90053,10044,00051,7004,600
       Cash And Cash Equivalents 
4,400
27,600
11,600
28,600
71,600
28,400
34,900
71,500
24,200
31,500
322,090
189,205
108,098
98,159
55,006
78,045
213,171
355,663
389,115
446,658
243,197
475,320
489,407
569,299
625,259
714,768
1,183,945
1,665,412
2,650,134
3,109,322
5,988,187
6,795,000
10,504,000
10,372,300
10,372,30010,504,0006,795,0005,988,1873,109,3222,650,1341,665,4121,183,945714,768625,259569,299489,407475,320243,197446,658389,115355,663213,17178,04555,00698,159108,098189,205322,09031,50024,20071,50034,90028,40071,60028,60011,60027,6004,400
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
66,509
553,997
526,886
485,005
337,314
283,112
491,455
105,208
442,986
838,255
788,214
493,602
831,808
895,777
761,847
327,694
250,612
423,254
518,108
698,972
670,710
729,900
274,500
849,200
849,200274,500729,900670,710698,972518,108423,254250,612327,694761,847895,777831,808493,602788,214838,255442,986105,208491,455283,112337,314485,005526,886553,99766,5090000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
5,900
12,262
20,265
13,200
7,324
11,891
20,595
62,923
31,320
23,489
9,601
12,529
183,135
143,250
85,517
72,994
177,639
201,083
281,343
409,688
633,518
885,352
1,136,800
1,442,200
1,563,400
1,563,4001,442,2001,136,800885,352633,518409,688281,343201,083177,63972,99485,517143,250183,13512,5299,60123,48931,32062,92320,59511,8917,32413,20020,26512,2625,900000000000
       Other Current Assets 
200
24,100
32,400
24,500
35,300
59,500
97,300
210,100
224,500
157,800
2,325
5,989
4,039
3,318
2,501
3,303
3,857
4,660
11,991
12,512
13,099
983,811
24,673
23,836
57,193
12,065
16,780
63,964
74,045
213,515
308,353
187,200
74,400
620,500
620,50074,400187,200308,353213,51574,04563,96416,78012,06557,19323,83624,673983,81113,09912,51211,9914,6603,8573,3032,5013,3184,0395,9892,325157,800224,500210,10097,30059,50035,30024,50032,40024,100200
   > Long-term Assets 
4,600
5,400
7,000
7,900
9,300
11,100
11,300
14,000
17,600
37,200
369,695
149,039
159,148
130,605
138,741
163,943
150,173
104,626
112,898
648,462
668,407
873,026
1,169,703
730,465
788,168
1,141,951
1,132,779
1,062,686
2,543,608
3,709,151
3,926,782
4,417,700
5,469,600
8,586,000
8,586,0005,469,6004,417,7003,926,7823,709,1512,543,6081,062,6861,132,7791,141,951788,168730,4651,169,703873,026668,407648,462112,898104,626150,173163,943138,741130,605159,148149,039369,69537,20017,60014,00011,30011,1009,3007,9007,0005,4004,600
       Property Plant Equipment 
4,400
5,000
6,900
7,700
8,500
7,800
8,700
11,100
14,500
24,500
28,149
80,377
95,991
80,083
64,225
54,533
61,535
66,509
68,331
62,279
72,333
133,176
433,609
696,911
715,812
697,715
698,362
789,437
812,005
745,080
958,534
1,094,100
1,108,400
1,452,900
1,452,9001,108,4001,094,100958,534745,080812,005789,437698,362697,715715,812696,911433,609133,17672,33362,27968,33166,50961,53554,53364,22580,08395,99180,37728,14924,50014,50011,1008,7007,8008,5007,7006,9005,0004,400
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
26,102
26,102
30,992
30,992
30,992
39,915
50,384
50,384
50,384
50,384
1,402,158
1,402,158
1,402,200
1,088,000
1,088,000
1,088,0001,088,0001,402,2001,402,1581,402,15850,38450,38450,38450,38439,91530,99230,99230,99226,10226,1020000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,000
20,276
20,447
13,600
60,800
0
0
112,200
2,497,800
2,497,800112,2000060,80013,60020,44720,27630,0000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
518,700
518,700
663,500
663,500
105,800
29,000
284,340
284,340
29,000
50,384
400,000
400,000
400,000
603,600
839,900
839,900603,600400,000400,000400,00050,38429,000284,340284,34029,000105,800663,500663,500518,700518,7000000000000000000000
       Long-term Assets Other 
200
400
100
200
800
3,300
2,600
2,900
3,100
12,700
341,546
68,662
36,724
31,659
55,653
90,547
88,638
38,117
44,567
41,381
51,272
45,358
41,602
2,562
3,441
109,512
99,693
193,865
181,547
326,943
662,511
901,100
1,323,300
796,700
796,7001,323,300901,100662,511326,943181,547193,86599,693109,5123,4412,56241,60245,35851,27241,38144,56738,11788,63890,54755,65331,65936,72468,662341,54612,7003,1002,9002,6003,300800200100400200
> Total Liabilities 
4,000
4,900
7,100
11,500
10,700
13,700
12,700
19,600
20,100
23,200
385,984
449,780
437,139
531,566
510,012
309,822
415,644
330,182
741,605
858,550
1,221,473
1,238,768
1,524,906
962,636
1,240,126
1,404,365
1,555,594
1,503,708
1,810,695
2,233,221
3,064,993
3,332,500
4,238,200
5,149,800
5,149,8004,238,2003,332,5003,064,9932,233,2211,810,6951,503,7081,555,5941,404,3651,240,126962,6361,524,9061,238,7681,221,473858,550741,605330,182415,644309,822510,012531,566437,139449,780385,98423,20020,10019,60012,70013,70010,70011,5007,1004,9004,000
   > Total Current Liabilities 
1,600
2,700
3,900
7,300
6,000
8,800
7,100
13,700
13,100
18,500
38,671
91,553
64,597
139,067
153,745
100,243
251,014
199,279
216,564
666,507
474,783
838,768
432,624
397,829
368,254
506,349
7,954
807,260
715,482
1,204,522
1,560,110
1,873,600
2,430,600
3,547,400
3,547,4002,430,6001,873,6001,560,1101,204,522715,482807,2607,954506,349368,254397,829432,624838,768474,783666,507216,564199,279251,014100,243153,745139,06764,59791,55338,67118,50013,10013,7007,1008,8006,0007,3003,9002,7001,600
       Short-term Debt 
800
1,200
1,800
1,800
1,700
2,100
2,900
2,500
2,800
2,400
2,377
4,579
2,195
4,660
94,656
59,596
103,758
19,997
105,871
32,071
136,991
195,378
13,707
16,893
32,012
87,023
319,426
22,531
9,817
30,293
42,434
46,900
89,400
83,700
83,70089,40046,90042,43430,2939,81722,531319,42687,02332,01216,89313,707195,378136,99132,071105,87119,997103,75859,59694,6564,6602,1954,5792,3772,4002,8002,5002,9002,1001,7001,8001,8001,200800
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,206
71,296
300,000
606,433
0
0
0
0
0
0
000000606,433300,00071,29614,206000000000000000000000000
       Accounts payable 
0
800
700
3,500
1,400
3,000
1,400
4,200
2,800
3,000
3,847
11,628
16,745
12,306
6,660
6,210
15,368
32,750
51,760
36,989
35,851
74,642
101,292
49,327
71,194
74,942
61,451
73,994
110,987
87,610
155,139
195,000
303,900
364,900
364,900303,900195,000155,13987,610110,98773,99461,45174,94271,19449,327101,29274,64235,85136,98951,76032,75015,3686,2106,66012,30616,74511,6283,8473,0002,8004,2001,4003,0001,4003,5007008000
       Other Current Liabilities 
800
700
1,400
2,000
2,900
3,700
2,800
7,000
7,500
13,100
32,447
35,848
33,769
114,355
4,688
2,988
97,999
121,004
21,255
296,916
227,322
405,616
290,059
310,099
247,580
328,088
-452,344
473,165
40,589
1,024,287
1,171,018
1,460,000
1,877,700
2,928,500
2,928,5001,877,7001,460,0001,171,0181,024,28740,589473,165-452,344328,088247,580310,099290,059405,616227,322296,91621,255121,00497,9992,9884,688114,35533,76935,84832,44713,1007,5007,0002,8003,7002,9002,0001,400700800
   > Long-term Liabilities 
2,400
2,200
3,200
4,200
4,700
4,900
5,600
5,900
7,000
4,700
347,313
358,227
372,542
392,499
356,267
209,579
164,630
130,903
525,041
192,043
746,690
400,000
1,524,906
962,636
1,240,126
1,404,365
1,547,640
1,503,708
1,095,213
1,028,699
1,504,883
1,458,900
1,807,600
1,602,400
1,602,4001,807,6001,458,9001,504,8831,028,6991,095,2131,503,7081,547,6401,404,3651,240,126962,6361,524,906400,000746,690192,043525,041130,903164,630209,579356,267392,499372,542358,227347,3134,7007,0005,9005,6004,9004,7004,2003,2002,2002,400
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
400,000
455,950
683,201
489,691
792,935
739,503
521,335
583,902
581,550
538,576
539,042
0
0
0
000539,042538,576581,550583,902521,335739,503792,935489,691683,201455,950400,00000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
35,201
46,598
59,039
21,270
29,482
144,633
130,903
237,541
292,216
186,412
146,763
128,714
75,116
62,263
159,395
244,724
112,546
108,853
275,526
923,407
902,200
685,800
0
0685,800902,200923,407275,526108,853112,546244,724159,39562,26375,116128,714146,763186,412292,216237,541130,903144,63329,48221,27059,03946,59835,20100000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
320,327
361,802
376,609
49,459
42,852
120,153
140,695
8,067
0
0
0
0
0
0
0000008,067140,695120,15342,85249,459376,609361,802320,32700000000000000000000
> Total Stockholder Equity
5,200
52,200
43,900
49,500
105,500
85,300
130,800
276,000
246,200
209,200
386,897
475,351
378,581
192,845
35,441
239,176
505,935
271,295
238,874
1,096,946
503,973
786,843
999,180
1,356,405
1,096,183
1,092,680
1,338,191
2,042,306
4,435,203
6,085,244
8,686,815
10,100,000
13,912,700
17,580,400
17,580,40013,912,70010,100,0008,686,8156,085,2444,435,2032,042,3061,338,1911,092,6801,096,1831,356,405999,180786,843503,9731,096,946238,874271,295505,935239,17635,441192,845378,581475,351386,897209,200246,200276,000130,80085,300105,50049,50043,90052,2005,200
   Common Stock
0
0
0
0
0
0
0
0
0
300
596
751
764
780
807
1,081
1,244
1,312
1,494
1,982
2,016
2,072
2,149
2,320
2,385
2,427
2,450
2,512
2,546
2,589
2,599
2,500
2,600
2,600
2,6002,6002,5002,5992,5892,5462,5122,4502,4272,3852,3202,1492,0722,0161,9821,4941,3121,2441,081807780764751596300000000000
   Retained Earnings 
-6,200
-11,400
-19,900
-17,800
-35,400
-56,900
-96,900
-116,800
-149,900
-190,800
-230,485
-314,532
-423,153
-619,920
-786,167
-989,584
-1,196,475
-1,587,754
-2,047,605
-2,689,783
-3,444,409
-3,414,835
-3,521,867
-3,966,895
-4,705,450
-5,261,784
-5,373,836
-5,119,723
-2,989,478
-1,852,978
858,669
3,200,800
6,522,800
10,142,400
10,142,4006,522,8003,200,800858,669-1,852,978-2,989,478-5,119,723-5,373,836-5,261,784-4,705,450-3,966,895-3,521,867-3,414,835-3,444,409-2,689,783-2,047,605-1,587,754-1,196,475-989,584-786,167-619,920-423,153-314,532-230,485-190,800-149,900-116,800-96,900-56,900-35,400-17,800-19,900-11,400-6,200
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,947,433
4,200,659
4,519,448
5,321,286
5,777,154
6,197,500
6,506,795
7,157,362
7,421,476
7,937,606
7,894,027
6,880,800
7,386,500
0
07,386,5006,880,8007,894,0277,937,6067,421,4767,157,3626,506,7956,197,5005,777,1545,321,2864,519,4484,200,6593,947,43300000000000000000000
   Treasury Stock0000000000000000000000000000000000
   Other Stockholders Equity 
11,400
63,600
63,800
67,300
140,900
142,200
247,700
416,400
424,200
434,100
659,381
858,031
794,206
810,407
833,832
1,243,960
1,702,128
1,856,856
2,281,817
3,784,787
3,947,433
4,200,659
4,519,448
5,321,286
5,777,154
6,197,500
6,506,795
7,157,362
7,421,476
7,937,606
7,894,027
6,880,800
7,386,500
7,449,700
7,449,7007,386,5006,880,8007,894,0277,937,6067,421,4767,157,3626,506,7956,197,5005,777,1545,321,2864,519,4484,200,6593,947,4333,784,7872,281,8171,856,8561,702,1281,243,960833,832810,407794,206858,031659,381434,100424,200416,400247,700142,200140,90067,30063,80063,60011,400



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue9,839,000
Cost of Revenue-1,262,200
Gross Profit8,576,8008,576,800
 
Operating Income (+$)
Gross Profit8,576,800
Operating Expense-4,826,600
Operating Income3,750,2003,750,200
 
Operating Expense (+$)
Research Development3,690,000
Selling General Administrative1,136,600
Selling And Marketing Expenses0
Operating Expense4,826,6004,826,600
 
Net Interest Income (+$)
Interest Income614,700
Interest Expense-44,100
Other Finance Cost-0
Net Interest Income570,600
 
Pretax Income (+$)
Operating Income3,750,200
Net Interest Income570,600
Other Non-Operating Income Expenses0
Income Before Tax (EBT)4,379,8003,120,600
EBIT - interestExpense = 3,706,100
4,379,800
3,663,700
Interest Expense44,100
Earnings Before Interest and Taxes (EBIT)3,750,2004,423,900
Earnings Before Interest and Taxes (EBITDA)3,931,500
 
After tax Income (+$)
Income Before Tax4,379,800
Tax Provision-760,200
Net Income From Continuing Ops3,619,6003,619,600
Net Income3,619,600
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses6,088,800
Total Other Income/Expenses Net629,600-570,600
 

Technical Analysis of Vertex Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Vertex Pharmaceuticals Inc. The general trend of Vertex Pharmaceuticals Inc is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Vertex Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Vertex Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 406.86 < 406.97 < 421.45.

The bearish price targets are: 391.01 > 387.42 > 356.71.

Tweet this
Vertex Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Vertex Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Vertex Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Vertex Pharmaceuticals Inc. The current macd is -2.72629072.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Vertex Pharmaceuticals Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Vertex Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Vertex Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Vertex Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartVertex Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Vertex Pharmaceuticals Inc. The current adx is 21.98.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Vertex Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Vertex Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Vertex Pharmaceuticals Inc. The current sar is 392.00.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Vertex Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Vertex Pharmaceuticals Inc. The current rsi is 48.64. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Vertex Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartVertex Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Vertex Pharmaceuticals Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Vertex Pharmaceuticals Inc price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Vertex Pharmaceuticals Inc Daily Stochastic Oscillator ChartVertex Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Vertex Pharmaceuticals Inc. The current cci is 60.82.

Vertex Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartVertex Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Vertex Pharmaceuticals Inc. The current cmo is 4.74807987.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Vertex Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartVertex Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Vertex Pharmaceuticals Inc. The current willr is -36.62680931.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Vertex Pharmaceuticals Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Vertex Pharmaceuticals Inc Daily Williams %R ChartVertex Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Vertex Pharmaceuticals Inc. The current atr is 7.57476775.

Vertex Pharmaceuticals Inc Daily Average True Range (ATR) ChartVertex Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Vertex Pharmaceuticals Inc. The current obv is 86,694,443.

Vertex Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartVertex Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Vertex Pharmaceuticals Inc. The current mfi is 50.35.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Vertex Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartVertex Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Vertex Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-24CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Vertex Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Vertex Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.640
Ma 20Greater thanMa 50398.431
Ma 50Greater thanMa 100409.298
Ma 100Greater thanMa 200413.873
OpenGreater thanClose401.500
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Vertex Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Vertex Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Vertex Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Vertex Pharmaceuticals Inc

I send you an email if I find something interesting about Vertex Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Vertex Pharmaceuticals Inc.

Receive notifications about Vertex Pharmaceuticals Inc in your mailbox!